Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. director Yoseph Bornstein filed an initial Form 3 reporting his holdings of stock options to purchase the company’s ordinary shares. The filing lists four option grants with different exercise prices, vesting schedules, and expiration dates.
One grant covers 200 underlying shares at an exercise price of $241.47, fully vested and expiring on June 22, 2031. Two additional grants each relate to 2,166 underlying shares, with exercise prices of $25.21 and $26.56 and expirations on April 30, 2033 and May 7, 2034, respectively; portions of these are already vested and the rest vest in specified quarterly installments. A larger grant covers 16,000 underlying shares at an exercise price of $2.18, expiring on January 25, 2030, with all of these options vesting in sixteen equal quarterly installments from April 25, 2026 through January 25, 2030.
The footnotes explain that, to qualify for certain Israeli tax benefits under Section 102, plan securities are held in the name of a trustee, and that the exercise prices were originally denominated in New Israeli Shekels and converted to U.S. dollars using a Bank of Israel exchange rate of 3.106 NIS per USD reported on March 11, 2026.
Can-Fite BioPharma director Abraham Sartani reported existing holdings of stock options to purchase Ordinary Shares. The Form 3 lists multiple option series with different exercise prices and expirations, showing his current derivative position rather than new market trades.
Examples include options over 16 shares at an exercise price of 2826.1400 per share expiring on November 8, 2027, and options over 2,166 shares at 25.2100 per share expiring on April 30, 2033. Another grant covers 16,000 shares at 2.1800 per share expiring on January 25, 2030.
Footnotes state that some grants are fully vested and exercisable, while others vest in scheduled quarterly installments between April 1, 2026 and January 25, 2030, contingent on Sartani’s continued service. Exercise prices were originally set in New Israeli Shekels and are presented here in U.S. dollars using a Bank of Israel exchange rate.
Can-Fite BioPharma Ltd. VP Business Development Sari Fishman filed an initial Form 3 showing holdings of multiple option grants to purchase Ordinary Shares. These options were granted between 2017 and 2025 with exercise prices originally set in New Israeli Shekels and translated into U.S. dollars.
Some option grants are already fully vested and exercisable, while others vest in scheduled quarterly installments between 2026 and 2029, contingent on continued service. To qualify for Israeli Section 102 tax benefits, the options are held in the name of a trustee.
Can-Fite BioPharma Ltd. director and Chief Scientific Officer Pnina Fishman reported her initial holdings on a Form 3. She directly holds several option grants to purchase Ordinary Shares with exercise prices ranging from USD 17.39 to USD 2,264.01, plus 88 Ordinary Shares. Some options are fully vested and exercisable, while others continue vesting in quarterly installments through dates extending to June 30, 2029, subject to her continued service.
Can-Fite BioPharma Ltd. executive Motti Farbstein, who serves as CEO, CFO and COO, files an initial Form 3 disclosing his holdings of stock options on the company’s ordinary shares. The filing lists several direct option grants with exercise prices ranging from $17.47 to $2,439.02 per share and expirations from 2027 through 2035. Some grants are fully vested and exercisable, while others continue to vest in scheduled quarterly installments through 2029, subject to his continued service. The options were issued under Can-Fite’s 2003, 2013 and 2023 share option plans, and for Israeli tax purposes are registered in the name of a trustee.
Can-Fite BioPharma Ltd. reports that the Israeli Patent Office has allowed its patent application covering the use of A3 adenosine receptor agonists, including its lead drug Namodenoson, to induce fat loss and treat obesity and related metabolic disorders. This strengthens the company’s global intellectual property around Namodenoson’s anti-obesity activity, following similar patent advances in the US, Canada and Australia. The company highlights preclinical and clinical data suggesting Namodenoson can reduce fat accumulation and improve metabolic profiles, offering a differentiated mechanism from current GLP-1 obesity drugs. The global obesity treatment market is projected to reach $60.5 billion by 2030, growing at a compound annual rate of about 22%.
Can-Fite BioPharma Ltd. reported that a Special General Meeting of Shareholders held on March 10, 2026 approved all three proposals presented to shareholders. These proposals were previously outlined in the company’s Notice and Proxy Statement dated January 27, 2026, which had been furnished on Form 6-K.
Can-Fite Biopharma Ltd. is updating its Form F-1 registration (Registration No. 333-288890) via a prospectus supplement dated March 5, 2026 to cover up to 1,250,000 American Depositary Shares (representing 2,500,000 ordinary shares) and related warrants and pre-funded warrants.
The supplement incorporates a Form 6-K describing an inducement arrangement: a holder agreed to exercise 795,869 Existing Warrants for cash at a reduced price of $5.00 per ADS, yielding approximately $4.0 million gross proceeds, and the Company will issue New Warrants to purchase 1,591,738 ADSs at $5.00. The Company engaged H.C. Wainwright as placement agent with a 7.0% cash fee, a 1.0% management fee and Placement Agent Warrants to purchase 55,711 ADSs at an exercise price of $6.25. The closing was expected on or about March 5, 2026, and the Company agreed to file a resale registration statement and use commercially reasonable efforts to have it declared effective within 90 days.
Can-Fite BioPharma Ltd. entered a definitive inducement agreement leading to the immediate cash exercise of warrants to purchase 795,869 ADSs at a reduced exercise price of $5.00 per ADS, generating expected gross proceeds of approximately $4.0 million before fees.
In return, the investor will receive new unregistered warrants to purchase up to 1,591,738 ADSs at $5.00 per ADS, exercisable until two years after the effectiveness of a resale registration statement. H.C. Wainwright & Co. will receive fees, expense reimbursements and warrants for 55,711 ADSs. Can-Fite plans to use net proceeds for research and development, clinical trials, and general corporate purposes.
Can-Fite BioPharma Ltd. reported that its drug candidate namodenoson successfully met the primary endpoint of safety in a Phase 2a study for advanced pancreatic ductal adenocarcinoma. In this open-label trial, 20 heavily pretreated patients received namodenoson, and the treatment was described as very well tolerated with no new safety signals.
The safety profile in pancreatic cancer was consistent with prior experience in other oncological indications. Secondary endpoints include overall survival and progression-free survival; survival follow-up is ongoing, with about one-third of patients alive at the data cut-off. Namodenoson, a selective A3 adenosine receptor agonist, has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also being studied in liver cancer and MASH.
Can-Fite BioPharma Ltd. reported that its drug candidate namodenoson successfully met the primary endpoint of safety in a Phase 2a study for advanced pancreatic ductal adenocarcinoma. In this open-label trial, 20 heavily pretreated patients received namodenoson, and the treatment was described as very well tolerated with no new safety signals.
The safety profile in pancreatic cancer was consistent with prior experience in other oncological indications. Secondary endpoints include overall survival and progression-free survival; survival follow-up is ongoing, with about one-third of patients alive at the data cut-off. Namodenoson, a selective A3 adenosine receptor agonist, has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also being studied in liver cancer and MASH.